You were incredibly fortunate to find a doctor who is so well informed about such novel treatments from two of Australia’s ASX listed small cap biotech companies. I am also a Next Science Limited (NXS.ASX) shareholder. They developed the XPERIENCE® Advanced Surgical IrrigationX. While only anecdotal, I am pleased to learn that it worked well in combination with Recce’s R327 to treat your husband’s infection. I hope he experiences no further infections and is able to enjoy mobilising on his new ankle again shortly.
[WEBINAR REPLAY] What it takes to get a new drug to market in Australia, page-19
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RCE (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
51.0¢ |
Change
-0.015(2.86%) |
Mkt cap ! $118.1M | |||
| Open | High | Low | Value | Volume |
| 52.0¢ | 52.0¢ | 50.5¢ | $40.89K | 79.63K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 677 | 51.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 52.5¢ | 392 | 1 |
View Market Depth
| Last trade - 15.59pm 13/09/2024 (20 minute delay) ? |
| RCE (ASX) Chart |